Detalhe da pesquisa
1.
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Blood
; 135(18): 1517-1530, 2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107537
2.
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Br J Haematol
; 195(2): 230-243, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34341985
3.
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression.
Am J Hematol
; 95(10): 1158-1169, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602121
4.
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.
Haematologica
; 104(7): 1451-1459, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30655373
5.
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
Am J Hematol
; 96(7): E253-E257, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844864
6.
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
J Clin Oncol
; 41(7): 1393-1403, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215675
7.
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
Blood Cancer J
; 12(8): 119, 2022 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35982035
8.
Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
Cells
; 9(5)2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32429189
9.
Diagnostic work up of an adult female patient with systemic AA amyloidosis revealing the cause of infantile mental retardation.
Amyloid
; 25(1): 68-69, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29166802